4DN.F Denali Therapeutics Inc
- Market cap
- EUR 2.86B
- P/E
- -
- P/B
- 3.49x
- ROE
- -26.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 4DN.F undervalued?
Graham numberThe Graham number of Denali Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Denali Therapeutics Inc fundamental analysis
No fundamental analysis for Denali Therapeutics Inc yet.
Denali Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enz…
Full company profileDenali Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Denali Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 129M | 26.7M | 336M | 48.7M | 108M | 331M | 0.00 | 0.00 | 28.5M |
| Operating Income | -87.4M | -90.1M | -46.4M | -213M | 62.7M | -296M | -341M | -197M | -502M | -555M | -526M |
| EBITDA | - | -87.1M | -39.0M | -205M | 71.2M | - | -330M | -180M | -493M | -541M | -509M |
| Net Income | -86.7M | -88.2M | -36.2M | -198M | 71.1M | -291M | -326M | -145M | -423M | -513M | -248M |
| EPS | - | -1.01 | -0.38 | -2.05 | 0.59 | -2.38 | -2.40 | -1.05 | -2.94 | -3.28 | -1.55 |
| Balance Sheet | |||||||||||
| Total Assets | 271M | 487M | 662M | 553M | 1.60B | 1.40B | 1.46B | 1.15B | 1.37B | 1.14B | 1.26B |
| Total Liabilities | 16.5M | 20.9M | 115M | 158M | 454M | 442M | 418M | 123M | 144M | 131M | 330M |
| Shareholders' Equity | 255M | 466M | 547M | 395M | 1.15B | 962M | 1.04B | 1.03B | 1.23B | 1.01B | 926M |
| Cash & Short-term Investments | 39.9M | 218M | 77.1M | 79.4M | 507M | 293M | 218M | 127M | 175M | 205M | 103M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -71.9M | -76.6M | 50.1M | -152M | 416M | -211M | -245M | -358M | -348M | -413M | -461M |
| Capital Expenditure | 6.13M | 2.88M | 3.39M | 17.9M | 3.10M | 8.50M | 17.8M | 12.9M | 15.9M | 9.50M | 53.7M |
| Free Cash Flow | - | -79.5M | 46.7M | -169M | 413M | -220M | -263M | -371M | -364M | -422M | -515M |
| Ratios | |||||||||||
| ROE | -34.0% | -18.9% | -6.6% | -50.0% | 6.2% | -30.2% | -31.3% | -14.1% | -34.4% | -50.6% | -26.8% |
| ROA | -32.0% | -18.1% | -5.5% | -35.7% | 4.4% | -20.7% | -22.3% | -12.6% | -30.8% | -44.8% | -19.7% |
| Net Profit Margin | - | - | -28.1% | -740.7% | 21.2% | -597.2% | -300.6% | -43.9% | - | - | -869.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Denali Therapeutics Inc dividends
Denali Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Denali Therapeutics Inc
- Insiders 4.59%
- Institutions 95.41%
- Public & others 0.00%
- Shares outstanding 160M
- Free float 156M
Denali Therapeutics Inc company profile
- Company name
- Denali Therapeutics Inc
- Ticker
- 4DN.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 503
- Fiscal year end
- December
- Address
- 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 866 8547
- Website
- denalitherapeutics.com
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Denali Therapeutics Inc management
8- Dr. Ryan J. Watts Ph.D.Co-Founder, President, CEO & Director · born 1976
- Dr. Alexander O. Schuth M.D., Ph.D.Co-Founder, CFO, COO & Secretary · born 1973
- Dr. Dana AndersenChief Technical and Manufacturing Officer
- Mr. Joe Lewcock Ph.D.Chief Scientific Officer
- Mr. Chris Walsh J.D.General Counsel
- Ms. Cindy DunkleChief People Officer
- Ms. Katie Peng M.B.A.Chief Commercial Officer · born 1971
- Mr. Peter Chin M.D.Acting Chief Medical Officer & Head of Development · born 1968